Abstract
Between July 1994 and December 1996, PBSC were mobilized in 28 patients with poor-risk hematological malignancies and solid tumors. CD34+ cells were positively immunoselected using the Ceprate CS System. By December 1996, 22 patients had been reinfused with a median of 3.325 (0.078–9.5) × 106/kg CD34+ cells. In three patients unselected back-up PBSC had to be transfused along with selected CD34+ cells because of a CD34+ cell number <0.5 × 106/kg. G-CSF (10 μ g/kg) was started on day +1 and all patients engrafted within a median day number of 12 (range, 10–22) until leukocytes >1.0 × 109/l and a median day number of 56 (range, 10–180) until platelets >20.0 × 109/l (ie platelet transfusion independence). Time to leukocyte and platelet recovery was significantly shorter in patients receiving >2.0 × 106/kg purified CD34+ cells as compared to patients reinfused with <2.0 × 106/kg CD34+ cells. The hematopoietic recovery time was similar to that of 18 historical control patients treated with unseparated ABMT ± PBSCT with the exception of a significantly faster leukocyte engraftment in patients receiving >2.0 × 106/kg CD34+ cells and a significantly delayed platelet recovery time in patients receiving <2.0 × 106/kg purified CD34+ cells. There was a trend for a better overall survival and a lower probability of progression/relapse as compared to the historical controls. We observed five episodes of serious opportunistic infections (three pulmonary fungal infections, two cases of cryptosporidiosis) after the take. Four of these patients had been reinfused with <2.0 × 106/kg CD34+ cells probably indicating a delayed immune reconstitution after CD34+-selected PBSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nachbaur, D., Fink, FM., Nussbaumer, W. et al. CD34+-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-centre experience. Bone Marrow Transplant 20, 827–834 (1997). https://doi.org/10.1038/sj.bmt.1700981
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700981
Keywords
This article is cited by
-
Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation
International Journal of Hematology (2008)
-
Hemopoietic Recovery and Infectious Complications in Breast Cancer and Multiple Myeloma after Autologous CD34+ Cell-Selected Peripheral Blood Progenitor Cell Transplantation
International Journal of Hematology (2004)
-
Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells
Cancer Gene Therapy (2001)
-
CD34+-Selected Autologous Peripheral Blood Stem Cell Transplantation Conditioned With Total Body Irradiation for Malignant Lymphoma: Increased Risk of Infectious Complications
International Journal of Hematology (2001)
-
Effective high-dose chemotherapy combined with CD34+-selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T cell lymphoma
Bone Marrow Transplantation (2000)